Moreover, the B4galt1 inhibition and PD-1 blockade combination therapy group showed the most significant reduction in tumour burden compared with the other groups, and neither body weight loss nor other common toxic effects were observed (Fig. 7B-F). Here, B4GALT1 is linked to neoplasm.